Active, not recruitingPhase 1NCT01430390

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Studying Precursor B-cell acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Kevin Curran, MD
Memorial Sloan Kettering Cancer Center
Intervention
Biological/Genetically Modified T cells(biological)
Enrollment
19 enrolled
Eligibility
All sexes
Timeline
20112026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01430390 on ClinicalTrials.gov

Other trials for Precursor B-cell acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Precursor B-cell acute lymphoblastic leukemia

← Back to all trials